Cited by 107Sarcoma Diagnosis and TreatmentCancer therapeutics and mechanismsSynthesis and pharmacology of benzodiazepine derivatives

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer

Carter, Natalie J, Keam, Susan J·2007·Drugs

DOI 10.2165/00003495-200767150-00009

Open this paper in CoChat — free account

Abstract

Trabectedin (Yondelis); ET-743) is an antineoplastic agent that was originally derived from the Caribbean marine tunicate Ecteinascidia turbinata and is now produced synthetically. It binds to the minor groove of DNA, disrupting the cell cycle and inhibiting cell proliferation. Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents. It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer. In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer. In addition, its tolerability profile was generally manageable. The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.

Integrity signals

Registry

Crossref · 10.2165/00003495-200767150-00009

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer Statistics, 2007
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Parmar, M., Ledermann, J. A., Colombo, N., du Bois, A., Jf, D., Kristensen, G. B., Wheeler, S., Swart, A. M., Qian, W., Torri, V., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13718-x · Cited by 1,180
Soft-Tissue Sarcomas in Adults
Clark, M. A., Fisher, C., Judson, I. R., & Thomas, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041866 · Cited by 910
Soft Tissue Sarcomas
Cormier, J. N., & Pollock, R. E. (2004) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.94 · Cited by 861
Marine natural products as anticancer drugs
Simmons, T. L., Andrianasolo, E., McPhail, K., Flatt, P., & Gerwick, W. H. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.333.4.2 · Cited by 597
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J., Cesne, A. L., Sanfilippo, R. G., Casieri, P., Collini, P., Dileo, P., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70175-4 · Cited by 490
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Glabbeke, M. M. V., Verweij, J., Judson, I. R., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 462
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
Cesne, A. L., Blay, J., Judson, I. R., van Oosterom, A., Verweij, J., Radford, J. A., Lorigan, P. C., Rodenhuis, S., Ray-Coquard, I., Bonvalot, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.180 · Cited by 458
Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
García‐Carbonero, R., Supko, J., Manola, J. B., Seiden, M. V., Harmon, D. C., Ryan, D. P., Quigley, M., Merriam, P. A., Canniff, J., Goss, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.098 · Cited by 331
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
Yovine, A. J., Riofrio, M., Blay, J., Brain, E. G. C., Alexandre, J., Kahatt, C. M., Taamma, A., Jimeno, J. M., Martin, C., Salhi, Y., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.210 · Cited by 310
Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production
Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A. A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4037 · Cited by 287
Diagnosis and Management of Epithelial Ovarian Cancer
Bhoola, S. M., & Hoskins, W. J. (2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000220516.34053.48 · Cited by 205
Current Management Strategies for Ovarian Cancer
Aletti, G. D., Gallenberg, M. M., Cliby, W. A., Jatoi, A., & Hartmann, L. C. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.6.751 · Cited by 196
Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
García‐Carbonero, R., Supko, J. G., Maki, R. G., Manola, J. B., Ryan, D. P., Harmon, D. C., Puchalski, T. A., Goss, G., Seiden, M. V., Waxman, A. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.028 · Cited by 191
Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin
Herrero, A. B., Martı́n-Castellanos, C., Marco, E., Gago, F., & Moreno, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0179 · Cited by 172
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
Sessa, C., de Braud, F., Perotti, A., Bauer, J. A., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.032 · Cited by 162
In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients
Izbicka, E., Lawrence, R., Raymond, É., Eckhardt, G., Faircloth, G. T., Jimeno, J. M., Clark, G. M., & VonHoff, D. D. (1998) · Annals of Oncology · doi:10.1023/a:1008224322396 · Cited by 137
Management of Platinum-Sensitive Recurrent Ovarian Cancer
Pfisterer, J., & Ledermann, J. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.03.012 · Cited by 119
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
Laverdière, C., Kolb, E. A., Supko, J. G., Gorlick, R. G., Meyers, P. A., Maki, R. G., Wexler, L. H., Demetri, G. D., Healey, J. H., Huvos, A. G., et al. (2003) · Cancer · doi:10.1002/cncr.11563 · Cited by 98
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Takahashi, N., Li, W. W., Banerjee, D., Scotto, K. W., & Bertino, J. R. (2001) · PubMed · Cited by 96
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Li, W., Takahashi, N., Jhanwar, S. C., Cordon‐Cardo, C., Elisseyeff, Y., Jimeno, J. A., Faircloth, G. T., & Bertino, J. R. (2001) · PubMed · Cited by 93
Principles and practice of intraperitoneal chemotherapy for ovarian cancer
Fujiwara, K., Armstrong, D. K., Morgan, M. A., & Markman, M. M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00809.x · Cited by 91
The combination of yondelis and cisplatin is synergistic against human tumor xenografts
D’Incalci, M., Colombo, T., Ubezio, P., Nicoletti, I., Giavazzi, R., Erba, E., Ferrarese, L., Meco, D., Riccardi, R., Sessa, C., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00490-8 · Cited by 90
Ecteinascidin-743 inhibits activated but not constitutive transcription.
Friedman, D., Hu, Z., Kolb, E. A., Gorfajn, B., & Scotto, K. W. (2002) · PubMed · Cited by 89
The Management of Recurrent Ovarian Cancer
Bukowski, R. M., Ozols, R. F., & Markman, M. M. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.03.012 · Cited by 87
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
Zelek, L. H., Yovine, A. J., Brain, E. G. C., Turpin, F., Taamma, A., Riofrio, M., Spielmann, M., Jimeno, J. M., & Misset, J. L. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603142 · Cited by 86
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma
Grosso, F., Dileo, P., Sanfilippo, R. G., Stacchiotti, S., Bertulli, R., Piovesan, C., Jimeno, J. M., D’Incalci, M., Gescher, A. J., & Casali, P. G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.010 · Cited by 86
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
van Kesteren, C., Cvitkovic, E., Taamma, A., Lázaro, L. L., Jimeno, J. M., Guzmán, C., t, R. A. A. M., Schellens, J. H. M., Misset, J. L., Brain, E. G. C., et al. (2000) · PubMed · Cited by 79
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
Riccardi, R., Meco, D., Colombo, T., Ubezio, P., Zucchetti, M., Zaffaroni, M., Riccardi, A., Faircloth, G. T., Jose, J., & D’Incalci, M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0636-6 · Cited by 77
A Phase I and Pharmacokinetic Study of Ecteinascidin-743 (Yondelis) in Children with Refractory Solid Tumors. A Children's Oncology Group Study
Lau, L. M. S., Supko, J., Blaney, S. M., Hershon, L., Seibel, N. L., Krailo, M., Qu, W., Malkin, D. M., Jimeno, J. M., Bernstein, M. L., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.672.11.2 · Cited by 66
ET-743: a novel agent with activity in soft-tissue sarcomas
Fayette, J., Ray-Coquard, I. L., Alberti, L., Boyle, H. J., Méeus, P., Decouvelaere, A., Thiesse, P., Sunyach, M., Ranchère‐Vince, D., & Blay, J. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000228740.70379.3f · Cited by 66
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Donald, S., Verschoyle, R. D., Greaves, P., Gant, T. W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D’Incalci, M., Meco, D., et al. (2003) · PubMed · Cited by 64
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
Puchalski, T. A., Ryan, D. P., García‐Carbonero, R., Demetri, G. D., Butkiewicz, L., Harmon, D. C., Seiden, M. V., Maki, R. G., Lázaro, L. L., Jimeno, J. M., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0498-3 · Cited by 63
A phase II study of ET-743/trabectedin (`Yondelis') for patients with advanced gastrointestinal stromal tumours
Blay, J., Cesne, A. L., Verweij, J., Scurr, M. R., Seynaeve, C., Bonvalot, S., Hogendoorn, P. C. W., Jimeno, J. M., Evrard, V., Glabbeke, M. M. V., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.02.005 · Cited by 52
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi, K., Perdichizzi, S., Manara, M. C., Serra, M., Benini, S., Cerisano, V., Strammiello, R., Mercuri, M., Reverter‐Branchat, G., Faircloth, G. T., et al. (2002) · PubMed · Cited by 49
Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters
Minuzzo, M., Ceribelli, M., Pitarque, M., Borrelli, S., Erba, E., diSilvio, A., D’Incalci, M., & Mantovani, R. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.013615 · Cited by 42
In vitro interaction between Ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects
Simoens, C., Korst, A. E. C., Pooter, C. M. J. D., Lambrechts, H. A. J., Pattyn, G. G. O., Faircloth, G. T., Lardon, F., & Vermorken, J. B. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601431 · Cited by 41
Recent Developments in Salvage Chemotherapy for Patients with Metastatic Soft Tissue Sarcoma
Hartmann, J., & PATEL, S. R. (2005) · Drugs · doi:10.2165/00003495-200565020-00002 · Cited by 38
The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71
Manara, M. C., Perdichizzi, S., Serra, M., Pierini, R., Benini, S., Hattinger, C. M., Astolfi, A., Bagnati, R., D’Incalci, M., Picci, P., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.6.1605 · Cited by 37
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction
Brandon, E. F. A., Meijerman, I., Klijn, J. S., den Arend, D., Sparidans, R. W., Lázaro, L. L., Beijnen, J. H., & Schellens, J. H. M. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000180121.16407.38 · Cited by 36
In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
Brandon, E. F. A., Sparidans, R. W., Guijt, K.-J., Löwenthal, S., Meijerman, I., Beijnen, J. H., & Schellens, J. H. M. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-4538-9 · Cited by 36
Further Insight into the DNA Recognition Mechanism of Trabectedin from the Differential Affinity of Its Demethylated Analogue Ecteinascidin ET729 for the Triplet DNA Binding Site CGA
Marco, E., David‐Cordonnier, M., Bailly, C., Cuevas, C., & Gago, F. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060640y · Cited by 35
Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations
Shao, L., Kasanov, J., Hornicek, F. J., Morii, T., Fondren, G., & Weissbach, L. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.08.033 · Cited by 29
Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
Beumer, J. H., Rademaker-Lakhai, J. M., Rosing, H., Hillebrand, M. J. X., Bosch, T. M., Lázaro, L. L., Schellens, J. H. M., & Beijnen, J. H. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0342-2 · Cited by 29
Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
Kasper, B., Gil, T., & Awada, A. H. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32812143ef · Cited by 25
Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft
Riccardi, A., Meco, D., Ubezio, P., Mazzarella, G., Marabese, M., Faircloth, G. T., Jimeno, J. M., D’Incalci, M., & Riccardi, R. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000172837.67766.6a · Cited by 25
Metastatic Soft Tissue Sarcoma in Adults
Nielsen, O. S., Blay, J., Judson, I. R., Glabbeke, M. M. V., Verweij, J., & van Oosterom, A. T. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302030-00005 · Cited by 21
Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743
Marchini, S., Marrazzo, E., Bonomi, R., Chiorino, G., Zaffaroni, M., Weissbach, L., Hornicek, F. J., Broggini, M., Faircloth, G. T., & D’Incalci, M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.021 · Cited by 21
Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
Beumer, J. H., Buckle, T., Ouwehand, M., Franke, N. E. F., Lázaro, L. L., Schellens, J. H. M., Beijnen, J. H., & van Tellingen, O. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-7773-9 · Cited by 18
Soft Tissue Sarcoma
Goldberg, B. R. (2007) · Orthopaedic Nursing · doi:10.1097/00006416-200701000-00003 · Cited by 10
Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Leyvraz, S. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm046 · Cited by 7
7512 POSTER Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens
Cesne, A. L., von Mehren, M., Chawla, S., Blay, J., Schuetze, S. M., Nieto, A., Gomez, J., Santabarbara, P., Izquierdo, M. A., & Demetri, G. D. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71489-1 · Cited by 4
7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide
Chawla, S., Casali, P. G., von Mehren, M., Cesne, A. L., Blay, J., Lebedinsky, C. A., Alfaro, V., Elsayed, Y. A., Michiels, B., & Demetri, G. D. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71494-5 · Cited by 3
Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Vasey, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm017 · Cited by 3
7500 ORAL Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients (pts) with progressing leiomyosarcomas or liposarcomas (L-sarcomas)
Demetri, G. D., Schuetze, S. M., Cesne, A. L., Chawla, S., Casali, P. G., Gomez, J., Nieto, A., Elsayed, Y. A., Izquierdo, M. A., & Blay, J. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)71477-5 · Cited by 2

Research works printed but not linked: 8

Aletti, 2007, Mayo Clin Proc, 82, 751, 10.1016/S0025-6196(11)61196-8 · DOI
Friedman, 2002, Cancer Res, 62, 3377
Scotlandi, 2002, Clin Cancer Res, 8, 3893
Li, 2001, Clin Cancer Res, 7, 2908
Takahashi, 2001, Clin Cancer Res, 7, 3251
Manara, 2005, Int J Oncol, 27, 1605
Donald, 2003, Cancer Res, 63, 5902
van Kesteren, 2000, Clin Cancer Res, 6, 4725

Sorted by citations

Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,086
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases
Lordan, S., Ross, R. P., & Stanton, C. (2011) · Marine Drugs · doi:10.3390/md9061056 · Cited by 779
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
Demetri, G. D., Chawla, S. P., von Mehren, M., Ritch, P. S., Baker, L. H., Blay, J., Hande, K. R., Keohan, M. L., Samuels, B. L., Schuetze, S. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0088 · Cited by 537

See all 107

Authors: Carter, N. J., & Keam, S. J.
Affiliations: Wolters Kluwer Health (NZ)
Corresponding author: Carter, Natalie J
ORCID: Keam, Susan J
Venue: Drugs
Publisher: Springer Science and Business Media LLC
Published: 2007
Volume: 67
Issue: 15
Pages: 2257-2276
ISSN: 0012-6667 (ISSN-L)
DOI: 10.2165/00003495-200767150-00009
OpenAlex: W1981744051
Cited by: 107
References: 57
Citations by year: 2025: 3 · 2024: 5 · 2023: 2 · 2022: 11 · 2021: 4 · 2020: 4 · 2019: 5 · 2018: 1 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 4
FWCI: 10.83
Type: journal article
Language: en
Open access: closed
Locations: Drugs (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
Keywords: trabectedin, Ecteinascidia turbinata, marine natural products, soft tissue sarcoma, ovarian cancer, DNA minor groove binding, nucleotide excision repair, G2/M cell cycle arrest, drug resistance, pharmacokinetics, pharmacodynamics, combination chemotherapy, liposarcoma, leiomyosarcoma, platinum-sensitive ovarian cancer
MeSH terms: Trabectedin, Animals, Dioxoles, Female, Humans, Ovarian Neoplasms, Sarcoma, Randomized Controlled Trials as Topic, Antineoplastic Agents, Alkylating, Tetrahydroisoquinolines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks